A5046435487- Epilepsy research and treatment
- Neuroscience and Neuropharmacology Research
- Biosimilars and Bioanalytical Methods
- Pharmacological Effects and Toxicity Studies
- Bacterial Infections and Vaccines
- Pharmaceutical studies and practices
- Lipid Membrane Structure and Behavior
- 3D Printing in Biomedical Research
- Synthesis and Reactions of Organic Compounds
- Oral microbiology and periodontitis research
- Cholinesterase and Neurodegenerative Diseases
- Molecular Sensors and Ion Detection
- Parkinson's Disease Mechanisms and Treatments
- Electrochemical sensors and biosensors
University of Milano-Bicocca
2025
Fondazione IRCCS Istituto Neurologico Carlo Besta
2021-2024
Eleven calix[4]arene ligands, bearing zwitterionic α‐amino acids or charged ammonium sulfonate/carboxylate groups, are synthesized and screened for the binding to envelopes of three bacterial strain representatives Gram‐positive, Gram‐negative, mycobacteria. The is followed by on‐cell Saturation Transfer Difference Nuclear Magnetic Resonance (NMR) experiments directly on alive cells. While anionic tetrasulfonatocalixarene does not bind any strains significantly cationic calixarenes strongly...
Cenobamate (CNB) is a new anti-seizure medication (ASM) recently introduced in clinical practice after approval by the FDA and EMA for add-on treatment of focal onset seizures adult patients. Although its mechanism action has not been fully understood, CNB showed promising efficacy patients treated with concomitant ASMs. The accessibility could pave way refractory or drug-resistant epilepsies, which still affect at least one-third under pharmacological treatment. In this context, therapeutic...
Levodopa (L-DOPA) treatment, combined with the administration of dopa-decarboxylase inhibitors (DDCIs), is still most effective symptomatic treatment Parkinson’s disease (PD). Although its efficacy in early stage has been confirmed, complex pharmacokinetics (PK) increases variability intra-individual motor response, thus amplifying risk motor/non-motor fluctuations and dyskinesia. Moreover, it demonstrated that L-DOPA PK strongly influenced by several clinical, therapeutic, lifestyle...
Cenobamate (CNB), a recently approved antiseizure medication by the European Medicines Agency (EMA), serves as an adjunctive therapy for focal-onset seizures in adult patients unresponsive to at least two other treatments. Administered polytherapy, CNB can potentially interact with co-administered drugs epilepsy patients, necessitating dose adjustments and need effective therapeutic drug monitoring (TDM).